Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
暂无分享,去创建一个
Kayla L. Stratton | G. Armstrong | K. Ness | D. Green | M. Hudson | L. Robison | W. Leisenring | K. Oeffinger | G. Aune | E. Chow | Y. Yasui | L. Kremer | E. C. van Dalen | H. V. D. van der Pal | E. Feijen | J. Loonen | E. V. van Dalen | K. Stratton | D. Green
[1] M. H. van den Berg,et al. Risk and Temporal Changes of Heart Failure Among 5‐Year Childhood Cancer Survivors: a DCOG‐LATER Study , 2018, Journal of the American Heart Association.
[2] Elizabeth M. Wells,et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. , 2018, The Lancet. Oncology.
[3] P. Nathan,et al. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Strong,et al. Long‐term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report , 2018, Cancer.
[5] C. Pui,et al. Decreased relapsed rate and treatment‐related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials , 2017, Cancer.
[6] P. Douglas,et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Carmen L. Wilson,et al. Approach for Classification and Severity Grading of Long-term and Late-Onset Health Events among Childhood Cancer Survivors in the St. Jude Lifetime Cohort , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[8] M. Jarfelt,et al. Cardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO‐AML study , 2016, European journal of haematology.
[9] P. Nathan,et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. , 2016, The New England journal of medicine.
[10] E. Soliman,et al. Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy , 2016, Annals of Internal Medicine.
[11] G. Hortobagyi,et al. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. , 2015, European journal of cancer.
[12] H. Brisse,et al. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second‐line chemotherapy , 2015, Pediatric blood & cancer.
[13] H. Caron,et al. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Nathan,et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. , 2015, The Lancet. Oncology.
[15] Kevin C Oeffinger,et al. Individual prediction of heart failure among childhood cancer survivors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Colan,et al. Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association , 2013, Circulation.
[17] G. Armstrong,et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Great,et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial , 2010, The Lancet.
[19] M. Hauptmann,et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. , 2010, Archives of internal medicine.
[20] R. Hills,et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] John D Boice,et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] I. Bernstein,et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Steinberger,et al. Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group , 2008, Pediatrics.
[24] S. Raimondi,et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Marilyn Stovall,et al. Dose Reconstruction for Therapeutic and Diagnostic Radiation Exposures: Use in Epidemiological Studies , 2006, Radiation research.
[26] R. Hills,et al. Treatment for myeloid leukaemia of Down syndrome: population‐based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials , 2006, British journal of haematology.
[27] H. Caron,et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. , 2004, European journal of cancer.
[28] J. Cayuela,et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Hortobagyi,et al. A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer , 1989, American journal of clinical oncology.
[30] N. Geller,et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] C. Pui,et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. , 1981, The Journal of pediatrics.
[32] C. Coltman,et al. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. , 1980, Cancer research.
[33] C. Ronckers,et al. Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Caron,et al. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. , 2011, The Cochrane database of systematic reviews.
[35] H. Caron,et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.
[36] G. Roul,et al. [Anthracycline-induced cardiomyopathy]. , 2009, Presse medicale.
[37] H. Dickinson,et al. Cardioprotective interventions for cancer patients receiving anthracyclines. , 2008, The Cochrane database of systematic reviews.
[38] G. Dukart,et al. Mitoxantrone: an overview of safety and toxicity , 2004, Investigational New Drugs.
[39] T. Herman,et al. Phase I clinical trial of mitoxantrone: A new anthracenedione anticancer drug , 2004, Cancer Chemotherapy and Pharmacology.
[40] G. Mathé,et al. Cancer Chemo- and Immunopharmacology , 1980, Recent Results in Cancer Research.